Equity Overview
Price & Market Data
Price: $0.0₃1
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $151,349
Daily Volume: 0
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: generic
Country:
Details
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.